Ethylenedicysteine (EC)-drug conjugates compositions and methods for tissue specific disease imaging
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-051/00
A61M-036/14
A61M-036/00
출원번호
UP-0627299
(2007-01-25)
등록번호
US-7582281
(2009-09-16)
발명자
/ 주소
Yang, David J.
Liu, Chun W.
Yu, Dong Fang
Kim, E. Edmund
출원인 / 주소
Board of Regents, The University of Texas System
대리인 / 주소
Fulbright & Jaworski LLP
인용정보
피인용 횟수 :
1인용 특허 :
91
초록▼
The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used
The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.
대표청구항▼
What is claimed is: 1. A method of imaging a site within a subject comprising the steps of: a) administering to the subject an effective amount of a composition comprising a radionuclide-labeled bis-aminoethanethiol (BAT)-targeting ligand conjugate, wherein the BAT comprises two carboxylic acid moi
What is claimed is: 1. A method of imaging a site within a subject comprising the steps of: a) administering to the subject an effective amount of a composition comprising a radionuclide-labeled bis-aminoethanethiol (BAT)-targeting ligand conjugate, wherein the BAT comprises two carboxylic acid moieties and wherein a targeting ligand is conjugated to at least one carboxylic acid moiety of the BAT; and b) detecting signal from the site. 2. The method of claim 1, wherein the signal is a radioactive signal. 3. The method of claim 2, wherein detecting comprises performing emission tomography. 4. The method of claim 1, wherein a first targeting ligand is conjugated to a first carboxylic acid moiety of the BAT and wherein a second targeting ligand is conjugated to a second carboxylic acid moiety of the BAT. 5. The method of claim 1, wherein the emission tomography is positron emission tomography (PET). 6. The method of claim 1, wherein the emission tomography is single photon emission computed tomography (SPECT). 7. The method of claim 1, wherein the targeting ligand is a tissue-specific ligand. 8. The method of claim 1, wherein the subject is a mammal. 9. The method of claim 1, wherein the subject is a human. 10. The method of claim 1, wherein the site is in the heart, breast, ovary, prostate, endometrium, lung, brain, or liver. 11. The method of claim 10, wherein the site is in the heart. 12. The method of claim 1, wherein the site is an area of inflammation. 13. The method of claim 12, wherein the area of inflammation is an infection. 14. The method of claim 1, wherein the site is a tumor. 15. The method of claim 14, wherein the tumor is breast cancer, lung cancer, prostate cancer, ovarian cancer, brain cancer, liver cancer, cervical cancer, colon cancer, renal cancer, skin cancer, head & neck cancer, bone cancer, esophageal cancer, bladder cancer, uterine cancer, lymphatic cancer, stomach cancer, pancreatic cancer, testicular cancer, lymphoma, multiple myeloma, folate-positive cancer, or estrogen-positive cancer. 16. The method of claim 1, wherein the radioactive signal from the administered composition localizes at the site. 17. The method of claim 1, wherein the radionuclide is 99mTc, 188Re, 186Re, 183Sm, 166Ho, 90Y, 89Sr, 67Ga, 68Ga, 111In, 183Gd, 59Fe, 225Ac, 212Bi, 211At, 64Cu or 62Cu. 18. The method of claim 1, wherein the radionuclide-labeled bis-aminoethanethiol (BAT)-targeting ligand conjugate is a radionuclide-labeled ethylenedicysteine-targeting ligand conjugate. 19. The method of claim 1, wherein the targeting ligand is an anticancer agent, DNA topoisomerase inhibitor, antimetabolite, tumor marker, folate receptor targeting ligand, tumor apoptotic cell targeting ligand, tumor hypoxia targeting ligand, DNA intercalator, receptor marker, peptide, nucleotide, organ specific ligand, antibiotic, antifungal, antibody, glutamate pentapeptide, or an agent that mimics glucose. 20. The method of claim 19, wherein the targeting ligand is an anticancer agent. 21. The method of claim 20, wherein the anticancer agent is methotrexate, doxorubicin, tamoxifen, paclitaxel, topotecan, LHRII, mitomycin C, etoposide tomudex, podophyllotoxin, mitoxantrone, camptothecin, colchicine, endostatin, fludarabin, gemcitabine, or tomudex. 22. The method of claim 19, wherein the targeting ligand is a tumor marker. 23. The method of claim 22, wherein the tumor marker is PSA, ER, PR, CA-125, CA-199, CEA AFP, interferons, BRCA1, HER-2/neu, cytoxan, p53, endostatin, or a monoclonal antibody. 24. The method of claim 19, wherein the targeting ligand is a folate receptor targeting ligand. 25. The method of claim 24, wherein the folate receptor targeting ligand is folate, methotrexate, or tomudex. 26. The method of claim 19, wherein the targeting ligand is a tumor apoptotic cell targeting ligand. 27. The method of claim 26, wherein the tumor apoptotic cell targeting ligand is annexin V. 28. The method of claim 19, wherein the targeting ligand is a tumor hypoxia targeting ligand. 29. The method of claim 28, wherein the targeting ligand is nitroimidazole, mitomycin, or metronidazole. 30. The method of claim 19, wherein the targeting ligand is glutamate pentapeptide. 31. The method of claim 19, wherein the targeting ligand is an agent that mimics glucose. 32. The method of claim 31, wherein the agent that mimics glucose is glucosamine, deoxyglucose, neomycin, kanamycin, gentamicin, paromycin, amikacin, tobramycin, netilmicin, ribostamycin, sisomicin, micromicin, lividomycin, dibekacin, isepamicin, astromicin, or an aminoglycoside. 33. The method of claim 32, wherein the agent that mimics glucose is glucosamine or deoxyglucose. 34. The method of claim 1, wherein the radionuclide-labeled bis-aminoethanethiol (BAT)-targeting ligand conjugate further comprises a linker conjugating a carboxylic acid moiety of the BAT to the targeting ligand. 35. The method of claim 34, wherein the linker comprises a water soluble peptide, glutamic acid, aspartic acid, bromo ethylacetate, ethylene diamine, or lysine. 36. The method of claim 35, wherein said linker is glutamate peptide or poly-glutamic acid. 37. The method of claim 36, wherein the targeting ligand is estradiol, topotecan, paclitaxel, raloxifen, etoposide, doxorubricin, mitomycin C, endostatin, annexin V, LHRH, octreotide, VIP, methotrexate, or folic acid. 38. The method of claim 1, wherein detecting is performed from about 10 minutes to about 4 hours after administering to the subject the effective amount of the composition. 39. The method of claim 1, wherein the site is a site of infection, a tumor, an organ, hypoxic tissue, a myocardial infarction, apoptotic cells, Alzheimer's disease, or endometriosis. 40. The method of claim 39, wherein the site is a tumor. 41. The method of claim 39, wherein the site is an organ. 42. The method of claim 41, wherein the organ is heart, lung, brain, liver, spleen, pancreas, or intestine. 43. The method of claim 42, wherein the organ is heart. 44. The method of claim 43, wherein the site is an area of myocardial infarction.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (91)
Weitl Frederick L. (Martinez CA) Raymond Kenneth N. (Berkeley CA), 2,3-Dihydroxybenzoic acid amides of tetraazaalkanes and tetaaza cycloalkanes.
Torchilin Vladimir P. (41 ; 8th St. ; #3208 Charlestown MA 02129) Trubetskoy Vladimir S. (9 Morton Ter. Milton MA 02186) Wolf Gerald L. (5 Hawthorn Rd. Winchester MA 01890), Amphipathic polychelating compounds and methods of use.
Axworthy Donald B. (Brier WA) Theodore Louis J. (Lynnwood WA) Gustavson Linda M. (Seattle WA) Reno John M. (Brier WA), Biotinidase-resistant biotin-DOTA conjugates.
Bogdanov Alexei A. (Newton MA) Weissleder Ralph (Charlestown MA) Brady Thomas J. (Winchester MA) Callahan Ronald (Boston MA), Blood pool imaging composition and method of its use.
Low Philip Stewart (West Lafayette IN) Horn Mark Alan (Piscataway NJ) Heinstein Peter Frederick (West Lafayette IN), Composition and method for tumor imaging.
Nicolotti Robert A. (Furguson MO) Dean Richard T. (Chesterfield MO), Coupling agents for joining radionuclide metal ions with biologically useful proteins.
Linder Karen (Kingston NJ) Nunn Adrian D. (Ringoes NJ) Nowotnik David P. (Flemington NJ) Ramalingam Kondareddiar (Dayton NJ) DiRocco Richard J. (Allentown NJ) Rumsey William L. (Wyndmoor PA) Pirro Jo, Diagnostic imaging methods using rhenium and technetium complexes containing a hypoxia-localizing moiety.
Bergstein Paul L. (Norwood MA) Cheesman Edward H. (Townsend MA) Watson Alan D. (Andover MA), Ester-substituted diaminedithiols and radiolabeled complexes thereof.
Yang, David J.; Liu, Chun W.; Yu, Dong-Fang; Kim, E. Edmond, Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging.
Killat George R. (Midland MI) Tomalia Donald A. (Midland MI), Ion exchange/chelation resins containing dense star polymers having ion exchange or chelate capabilities.
Woodle Martin C. (Menlo Park CA) Martin Francis J. (San Francisco CA) Yau-Young Annie (Los Altos CA) Redemann Carl T. (Walnut Creek CA), Liposomes with enhanced circulation time.
Marzilli Luigi G. ; Lipowska Malgorzata ; Hansen Lory ; Taylor ; Jr. Andrew, Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof.
Marzilli Luigi Gaetano ; Lipowska Malgorzata ; Hansen Lory ; Taylor ; Jr. Andrew, Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof.
Srinivasan Ananthachari (Kirkland WA) Fritzberg Alan R. (Edmonds WA) Jones David S. (Seattle WA), Metal radionuclide chelating compounds for improved chelation kinetics.
Low Philip S. (West Lafayette IN) Horn Mark A. (West Lafayette IN) Heinstein Peter F. (West Lafayette IN), Method for enhanced transmembrane transport of exogenous molecules.
Low Philip S. (West Lafayette IN) Horn Mark A. (West Lafayette IN) Heinstein Peter F. (West Lafayette IN), Method for enhancing transmembrane transport of exogenous molecules.
Low Philip S. (West Lafayette IN) Horn Mark A. (West Lafayette IN) Heinstein Peter F. (West Lafayette IN), Method for enhancing transmembrane transport of exogenous molecules.
Tweedle Michael F. ; Gaughan Glen T.,GBX ; Hagan James J., Method for imaging and radiopharmaceutical therapy using 1-substituted-4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs.
Tweedle Michael F. (Princeton NJ) Gaughan Glen T. (Oxford GB2) Hagan James J. (Holmdel NJ), Method for imaging mammalian tissue using 1-substituted- 4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and anal.
Tweedle Michael F. ; Gaughan Glen T.,GB2 ; Hagan James J., Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analo.
Tweedle Michael F. (Hightstown NJ) Gaughan Glen T. (Oxford NJ GB2) Hagan James J. (Holmdel NJ), Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analog.
Skold Carl N. (Mountain View CA) Shanafelt Armen B. (Redwood City CA) Ghazarossian Vartan (Menlo Park CA) Ullman Edwin F. (Atherton CA), Method for immunochromatographic analysis.
Griffiths Gary L. (Morristown NJ) Hansen Hans J. (Mystic Island NJ) Karacay Habibe (Matawan NJ), Modified radioantibody fragments for reduced renal uptake.
Katti Kattesh V. (Columbia MO) Volkert Wynn A. (Columbia MO) Ketring Alan R. (Columbia MO) Singh Prahlad R. (Columbia MO), New multifunctional ligands for potential use in the design therapeutic or diagnostic radiopharmaceutical imaging agents.
Dunn T. Jeffrey (Cedar Mill MO) Nosco Dennis (Florissant MO) Woulfe Steven (Hazelwood MO) Dean Richard (Downingtown PA) Wester Dennis (Lynwood WA), Novel TC-99M complexes.
Hansen Hans J. (Mystic Island NJ) Leung Shui-on (Madison NJ) Shevitz Jerry (Livingston NJ) Griffiths Gary L. (Morristown NJ) Govindan Seregulam V. (Summit NJ), Preparation and use of immunoconjugates.
Papahadjopoulos Demetrios ; Hong Keelung ; Zheng Weiwen, Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery.
Lyle Leon R. (Webster Groves MO) Kunkel Steven L. (Ann Arbor MI) Strieter Robert M. (Ann Arbor MI), Radiolabeled neutrophil activating peptides for imaging.
Butterfield Dennis E. ; Fujii Dennis K. ; Ladd David L. ; Snow Robert A. ; Tan Julia S. ; Toner John L., Segmented chelating polymers as imaging and therapeutic agents.
Boguslaski Robert C. (Elkhart IN) Burd John F. (Elkhart IN) Carrico Robert J. (Elkhart IN), Specific binding assay employing an enzyme-cleavable substrate as label.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.